Welcome to Santegra!

Login

 
Lost your password?
 
×

Registration

Profile Informations

Login Datas

or login

First name is required!
Last name is required!
First name is not valid!
Last name is not valid!
This is not an email address!
Email address is required!
This email is already registered!
Password is required!
Enter a valid password!
Please enter 6 or more characters!
Please enter 16 or less characters!
Passwords are not same!
Terms and Conditions are required!
Email or Password is wrong!

LiverPro™ (90) | 15882

Be the first to review this product

Availability: Out of stock

Quick Overview

Contains SILIPHOS® - patented natural hepatoprotector, lipophilic complex of silybin and phosphatidylcholine; does not cause adverse reaction.  It is recognized as the most bioavailable form of silybin known today.

LiverPro™ (90)

Double click on above image to view full picture

Zoom Out
Zoom In

More Views

Details

All natural products Santegra USA, including LiverPro™, have been manufactured from all natural remedies using high quality pure raw materials and technology that ensures all their beneficial properties intact, in strict compliance with GMP and TÜV regulations.

The exclusive Santegra®’s product – LiverPro™ is the most powerful natural formula for liver health.

The liver is the largest and one of the most complex organs in the human body. It plays a central role in nearly all body functions. The liver is the first line of defense, the key organ in the body’s detoxification system, the powerful filter, which cleanses blood by filtering out the toxins that assault the body on a regular basis. The liver filters over a liter of blood each minute!

The liver, due to the vital role it plays in metabolism, is particularly exposed to the harmful action of toxins. Many potentially harmful substances, such as alcohol, drugs and other toxins are metabolized by the liver and transformed into hydro-soluble derivatives for subsequent biliary extraction and removal from the body. For this reason the upkeep of the integrity of the liver cell is necessary for the safeguarding of health.

Very dangerous for the liver are free radicals, because they are involved as starters or intermediates in several biochemical reactions, which constitute a continuous risk factor for the integrity of the hepatocytes. (1)

Fortunately, you can take steps to protect your liver:

Reduce your exposure to toxins, especially alcohol, fried, processed and junk foods;

Try to avoid overeating, because it creates excessive work for the liver.

The unique LiverPro™ formula will help you to normalize and maintain liver functions.

Name LiverPro™ (90)
Product Line Prescripta

Use spaces to separate tags. Use single quotes (') for phrases.

Usage

Take 3 capsules twice daily with a large glass of water with food as a dietary supplement.


Contraindication

Individual intolerance. Not intended for children.


Per one capsule:

SILIPHOS® (Milk Thistle Phytosome® - silybin (from Silybum Marianum L. Gaertn.) phosphatidylcholine complex) (contains 40 mg sylibin, 80 mg phosphatidylcholine) –120 mg.

Clinical studies have been performed to evaluate the properties of SILIPHOS® in subjects with impairment of liver function.

siliphos

Fig. 1

 

Vailati et al performed an open randomized trial on 65 patients suffering from chronic persistent hepatitis. The protective effects of SILIPHOS® increased with the dose and 240 mg/die p.o. (as silybin) resulted to be the mean therapeutic dose whereas 360 mg/die p.o. (as silybin) was recommended for the treatment of the severe resistant form of hepatitis or during the initial management of the patients. (5)
In a study carried out on 232 patients with alcoholic, acute viral or iatrogenic hepatitis, the subjects have been treated with 240 or 360 mg/die p.o. (as silybin) for 120 days. No side effects have been observed and SILIPHOS®, in comparison with placebo, showed its ability to improve liver condition. (6)

In a short-term pilot study performed on 20 patients with chronic active hepatitis, the biochemical parameters related to hepatocellular damage and necrosis were significantly reduced after 7 days of treatment with 240 mg/die p.o. (as silybin). (Fig. 1) (7)

A 2-month study on 8 patients complaining of chronic active hepatitis has shown the ability of SILIPHOS® to reduce serum MDA concentration and to increase galactose elimination by the liver.  (8)

A total of 18 cases of Amanita phalloides poisoning was treated by combined chemotherapy during 1980 and 1981. After attempted primary elimination of the toxin all patients received silybin as basic therapy mainly by infusion and, in two instances, silymarin orally. In order to investigate the effect of silybin therapy a retrospective study of the followed-up case records was made. The cases were arbitrarily classified into three groups of severity (light, medium and severe) according to clinical and laboratory findings. A close relationship was found between the severity of the intoxication and the time elapsed before commencement of silybin therapy. The time interval between mushroom intake and the commencement of the silybin administration averaged 71.5 hours in the "severe" group compared with 46 and 33.8 hours, respectively, in the "medium" and "light" groups. The mean silybin dosage was 33 mg/kg body weight/day; the mean duration of silybin therapy was 81.6 hours. With the exception of one fatality in a particularly high dosage suicidal intoxication, all patients survived.
Administration of silybin within about 48 hours after mushroom intake seems to be an effective measure to prevent severe liver damage in Amanita phalloides poisoning.

Research Brief As demonstrated by pharmacokinetic studies in comparison with free silybin and silymarin, SILIPHOS® represents the most absorbable form of silybin known until now.

siliphos_2-3-4_jpeg


After oral administration of 200 mg/kg of silybin, the plasma levels of this drug and its conjugated metabolites were below the analytical detection limit, while, after oral administration of SILIPHOS® (200 mg/kg as silybin) the plasma levels of silybin (free and total) were easily measurable (Fig. 2).(animal studies)

After oral administration of SILIPHOS®, the biliary elimination of silybin was not complete at 24 h and accounted for about 3.7% of the administered dose.  After administration of uncomplexed silybin, biliary elimination accounted for only 0.001%. (Fig. 3).

The compound was rapidly excreted in urine where at 72 h the amount recovered accounted for about 3.3%. After administration of uncomplexed silybin, urinary elimination accounted for only 0.032%. (Fig.4).

SILIPHOS® shows the same pharmacokinetic profile in man. After oral treatment, the bioavailability in healthy volunteers, in cholecystectomised patients or in patients suffering from hepatic cirrhosis is comparable to that demonstrated in animal models. (Fig. 2, 3, 4). (2, 10,11)

SILIPHOS® demonstrated a superior bioavailability which, as calculated for cumulative biliary excretion, resulted to be about 10-fold higher than that of the extract. (4)

The improvement of the oral bioavailability for SILIPHOS® is mainly dependent on a marked increase of its absorption in the gastrointestinal tract, most likely due to the lipophilic character of the complex. 
SILIPHOS® is to be considered a natural vehicle of silybin, the active botanical ingredient. SILIPHOS® allows silybin to reach the target organ, the liver, in concentrations which are reported to be effective in several models of liver intoxication. (9)

1. Schiff L., Schiff E.R., "Disease of the liver", V ed., J. B. Lippincott Co., Philadelphia, 1982.
2. Morazzoni P., Bombardelli E., Fitoterapia 50, 1 (1995).
3. Morazzoni P., Magistretti M.J., Giachetti C., Zanolo G., Eur. J. Drug Metabol. Pharmacokinet. 17, 39 (1992).
4. Morazzoni P., Montalbetti A., Malandrino S., Pifferi G., Eur. J. Drug Metabol. Pharmacokinet. 18, 289 (1993).
5. Vailati A., Aristia L., Sozzè E., Milani., Inglese V., Galenda P., Bossolo P.A., Ascari E., Lampertico M., Comis S., Marena G., Fitoterapia 64, 219 (1993).
6. Marena C., Lampertico M., Planta Med. 57, suppl., A124 (1991).
7. Buzzelli G., Moscarella S., Giusti A., Duchini A., Marena C., Lampertico M., Int. J. Clin. Pharmacol. Ther. Toxicol. 31, 456 (1993).
8. Moscarella S., Giusti A., Marra F., Marena C., Lampertico M., Relli P., Gentilini P., Buzzelli G., Curr. Ther.Res. 53, 98 (1993).
9. Conti M., Malandrino S., Magistretti M.J., Jpn J. Pharmacol. 60, 315 (1992).
10. Orlando R., Fragasso A., Lampertico M., Marena C., Med. Sci. Res. 19, 827 (1991).
11. Barzaghi N., Perucca E., Pifferi G.,  Crema A., Flavonoids in Biology and Medicine, Singapore, November 13-17, 1989.


 

Please wait...